


# Analysis of Sennosides in Senna in Accordance with the Japanese Pharmacopoeia

Senna contain total sennosides (sennoside A and sennoside B), making up more than 1.0 % of the dry weight of crude drugs. The Japanese Pharmacopoeia Law, 15th Edition, requires an HPLC method for the assay and the system conformity items listed below are defined.

In this study, Senna was analyzed using a HPLC system with an Inertsil ODS-4 column using the following conditions and conformed to the system suitability test defined below..

(K. Kanno)

## Example: measurement of standards



### HPLC conditions

Column	: Inertsil ODS-4 (5 µm, 150 x 4.6 mm I.D.)
Eluent	: A) CH <sub>3</sub> CN B) Acetate buffer *
	1 L of a mixture of A/B = 8/17 (v/v) bromide Tetra-n-heptylammonium Dissolve 2.45 g of m
Flow rate	: 0.8 mL/min.
Column temperature	: 50 °C
Detected	: UV 340 nm
Injection volume	: 10 µL

\* 100 mM sodium acetate, adjusted to pH 5.0 with glacial acetic acid




Figure 1 Calibration curve of sennoside.

## Requirements of the system suitability test

When analyzed under the above HPLC conditions,

1. Sennoside B and sennoside A are eluted in this order.
2. The resolution is 15 or greater.
3. The number of theoretical plates for sennoside A is not less than 8000.
4. The Relative standard deviation of the area value for the sennoside A peak when the analysis was repeated six times was not more than 1.5 %.

## Results


1. Elution order: Satisfies the provisions
2. Resolution: 21.8
3. Number of theoretical plates: 11800
4. Relative standard deviation: 1.06 % (Table 1)

\*See Technical Note No. 38.

Table 1. Area value and retention time of sennoside



	Area		RT (min)	
	Sennoside A	Sennoside B	Sennoside A	Sennoside B
1	2052022	3363820	23.8	9.8
2	2072734	3378712	23.8	9.8
3	2085026	3366048	23.8	9.8
4	2105586	3369100	23.9	9.9
5	2107927	3365150	23.9	9.9
6	2112802	3371409	23.8	9.9
Average	2089350	3369040	23.8	9.9
RSD (%)	1.14	0.16	0.20	0.24

## Structural formula



# Analysis of commercial senna powder

## Example of pretreatment



GL Sciences disclaims any and all responsibility for any injury or damage which may be caused by this data directly or indirectly. We reserve the right to amend this information or data at any time and without any prior announcement.

### **GL Sciences Inc. Japan**

22-1 Nishishinjuku 6-chome  
Shinjuku-ku, Tokyo  
163-1130, Japan

Phone: +81-3-5323-6620  
Fax: +81-3-5323-6621  
Email: [world@glsci.co.jp](mailto:world@glsci.co.jp)  
Web: [www.glsciences.com](http://www.glsciences.com)

### **GL Sciences Inc. USA**

4733 Torrance Blvd. Suite 255  
Torrance, CA 90503  
USA

Phone: +1-310-265-4424  
Fax: +1-310-265-4425  
Email: [info@glsciencesinc.com](mailto:info@glsciencesinc.com)  
Web: [www.glsciencesinc.com](http://www.glsciencesinc.com)

### **GL Sciences B.V.**

Dillenburgstraat 7C  
5652AM, Eindhoven  
The Netherlands

Phone: +31-40-254-9531  
Email: [info@glsciences.eu](mailto:info@glsciences.eu)  
Web: [www.glsciences.eu](http://www.glsciences.eu)

### **GL Sciences (Shanghai) Limited**

Tower B, Room 2003  
Far East International Plaza  
No.317 Xianxia Road, Changning District  
Shanghai, China 200051

Phone: +86-21-62782272  
Email: [contact@glsciences.com.cn](mailto:contact@glsciences.com.cn)  
Web: [www.glsciences.com.cn](http://www.glsciences.com.cn)



**International Distributors**

Visit our Website at [www.glsciences.com/distributors](http://www.glsciences.com/distributors)